50 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2038. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2038
Next term end
32
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2038 · High confidence
Also notable
Ends Jan 2039 · High confidence
Also notable
Ends Dec 2039 · High confidence
Also notable
Ends Jan 2039 · High confidence
Also notable
Ends Jul 2039 · High confidence
Also notable
Ends Oct 2038 · High confidence
Also notable
Ends Dec 2040 · High confidence
Also notable
Ends Dec 2038 · High confidence
Irak Degraders and Uses Thereof
US 10,874,743
The most cited patent in this portfolio, cited by 71 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2038.
Protein Degraders and Uses Thereof
US 11,485,743
Cited by 35 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
Irak Degraders and Uses Thereof
US 11,352,350
Cited by 26 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
CRBN Ligands and Uses Thereof
US 11,512,080
Cited by 30 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
Tricyclic CRBN Ligands and Uses Thereof
US 11,292,792
Cited by 39 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
CRBN Ligands and Uses Thereof
US 11,358,948
Cited by 31 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
Irak Degraders and Uses Thereof
US 11,779,578
Cited by 19 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Protein Degraders and Uses Thereof
US 11,623,932
Cited by 11 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 20 to 27, 2026 · next Dec 20
- 1 fee due Jan 25, 2027The maintenance fee for Irak Degraders and Uses Thereof (US 11,707,457) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Feb 15, 2027The maintenance fee for Irak Degraders and Uses Thereof (US 11,723,980) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Stat Degraders and Uses Thereof (US 11,746,120) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 2 fees due Apr 3 to 10, 2027 · next Apr 3
- 1 fee due May 7, 2027The maintenance fee for Irak Degraders and Uses Thereof (US 11,807,636) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Methods of Treating Mutant Lymphomas (US 11,857,535) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Tricyclic CRBN Ligands and Uses Thereof (US 11,897,882) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 2 fees due Sep 19, 2027
Recent changes
- 4 of the patents on this record were granted since Aug 22, 2026
What they patent
The largest of its 32 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Irak Degraders and Uses Thereof (2019) | 4 in force | to Jan 2040 |
| Irak Degraders and Uses Thereof (2018) | 4 in force | to Dec 2038 |
| Irak Degraders and Uses Thereof (2020) | 3 in force | to Jan 2041 |
| Stat Degraders and Uses Thereof | 3 in force | to Sep 2040 |
| Protein Degraders and Uses Thereof (2020) | 3 in force | to Jan 2039 |
| IRAK4 Degraders and Uses Thereof | 2 in force | to Feb 2042 |
| MDM2 Degraders and Uses Thereof | 2 in force | to Aug 2041 |
| Protein Degraders and Uses Thereof (2020) | 2 in force | to Feb 2041 |
| CRBN Ligands and Uses Thereof (2020) | 2 in force | to Dec 2040 |
| Tricyclic CRBN Ligands and Uses Thereof | 2 in force | to Jul 2039 |
| CRBN Ligands and Uses Thereof (2020) | 2 in force | to Jan 2039 |
| Irak Degraders and Uses Thereof (2022) | 1 in force | to Jul 2043 |
| Smarca Degraders and Uses Thereof | 1 in force | to Jun 2043 |
| Double Degraders and Uses Thereof | 1 in force | to May 2043 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,358,948 | CRBN Ligands and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,874,743 | Irak Degraders and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,318,205 | Irak Degraders and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,723,980 | Irak Degraders and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,168,057 | Irak Degraders and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,623,932 | Protein Degraders and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,485,743 | Protein Degraders and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,932,635 | CRBN Ligands and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,006,329 | Protein Degraders and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,516,068 | Protein Degraders and Uses Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 50: 58 applications pending · 22 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.